🚀 Why Netupitant-Palonosetron FDC is gaining momentum — and what’s next for oncology care
Cancer care is evolving — not just in therapies, but in supporting patient comfort. The Netupitant-Palonosetron fixed-dose combination (#FDC), increasingly regarded as a go-to antiemetic for chemotherapy- and surgery-induced nausea & vomiting, is riding a strong growth wave. According to a recent market report, the FDC market size was estimated at USD 1.268 billion in 2024, and is projected to nearly double to USD 2.619 billion by 2035, at a CAGR of ~6.8%.
read more - https://lnkd.in/djz83J_u
🔬 What’s fueling the growth?
Rising global cancer incidence → more patients require supportive care including antiemetic regimens.
Increasing recognition of patient-centric care: oncologists and care teams prioritizing quality of life, leading to higher adoption of effective and well-tolerated antiemetic combos like Netupitant-Palonosetron.
Advances in pharmaceutical research and evolving formulations — making therapy more effective, convenient and better accepted.
📈 Regional growth — Countries to watch
While North America remains the largest market today, the Asia-Pacific region is becoming the fastest-growing — driven by improving healthcare infrastructure, rising awareness, and increasing access to oncology care across emerging markets.
💡 What this means for stakeholders: Helsinn Group SA (CH), Hikma Pharmaceuticals PLC (GB), Mylan N.V. (US), Teva Pharmaceuticals Industries Ltd. (IL), AstraZeneca PLC (GB), Bristol Myers Squibb Company (US), Eisai US Co., Ltd. (JP), ROCHE LEON HOLDINGS AG (CH), Novartis (CH)
For oncology care providers and hospitals: Plan for growing demand — integrate antiemetic FDCs into standard care protocols for chemotherapy and postoperative care.
For pharma and generics manufacturers: Opportunity to expand production, develop newer formulations (oral, injectable, maybe even patient-friendly packaging), and tap into emerging markets.
For patients & advocacy groups: Improved options for nausea management — highlighting better adherence, fewer side-effects, and enhanced quality of life during treatment.
📄 For those interested in detailed market data and forecasts (2025–2035), you can refer to the latest report sample page - https://lnkd.in/daDXcJHq
#NetupitantPalonosetron,#FDCDrugs,#OncologyCare,#CancerSupportiveCare,#AntiemeticTherapy,#PharmaInnovation,#HealthcareMarket,#PharmaMarket,#DrugPipeline,#ClinicalResearch,#HealthcareTrends,#MarketInsights,#PatientCentricCare,#PrecisionMedicine,#HealthcareTechnology,#MedicalInnovation,#NetupitantPalonosetron #OncologyCare #PharmaInnovation #CancerSupportiveCare #HealthcareTrends #MarketInsights #PatientCentricCare #PharmaMarket